Avantor announced the creation of a new Scientific Advisory Board which will provide strategic guidance and consult on the company’s mid- to long-term research and development efforts to deliver solutions for the life sciences industry, including biotech and pharma customers. The SAB brings deep knowledge and experience in clinical research, academia, and industry to Avantor, and a passion for advancing science that improves health and well-being. By bringing together experts with a track record of working across innovative modalities, the SAB will enable Avantor to better serve customer needs as well as emerging opportunities and challenges facing the life sciences industry.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVTR:
- TOMI announces partnership with Avantor to expand presence of SteraMist
- Avantor partners with Tobin Scientific to provide end-to-end solution
- Avantor participates in a conference call with JPMorgan
- Avantor price target lowered to $24 from $27 at BofA
- Avantor price target lowered to $22 from $24 at Baird